Indication directory
Indications
Tryngolza and Dawnzera split by indication, not brand — open one to inspect policy posture, payer detail, competitive positioning, and launch access tracking.
Indications
3
Avg Policy Published
46%
YTD Updates
27
IndicationPrimary CompetitorPolicy PublishedTime to 1st PolicyYTD Updates
Tryngolza (FCS)
Ultra-rare lipid disorder — genetic/dx confirmation is the dominant PA criterion.
Waylivra
38%
5 mo
11
Tryngolza (sHTG)
Larger eligible population; payers lean on TG-threshold documentation and diet trial.
Vascepa / fibrates (SoC)
51%
4 mo
9
Dawnzera (HAE)
Prophylaxis market with established competitors — step-therapy exposure is the key risk.
Takhzyro, Orladeyo, Haegarda
49%
6 mo
7